Holen Sie sich die Stockscreener-App
16.57
1.35%
0.22
Vorhandelsmarkt:
16.65
0.08
+0.48%
Schlusskurs vom Vortag:
$16.35
Offen:
$16.16
24-Stunden-Volumen:
1.71M
Relative Volume:
0.44
Marktkapitalisierung:
$1.77B
Einnahmen:
$64.52M
Nettoeinkommen (Verlust:
$-95.55M
KGV:
-16.29
EPS:
-1.0169
Netto-Cashflow:
$-84.65M
1W Leistung:
+2.09%
1M Leistung:
-2.87%
6M Leistung:
+112.98%
1J Leistung:
+173.43%
1-Tages-Spanne:
$16.10
$16.63
1-Wochen-Bereich:
$16.07
$16.63
52-Wochen-Spanne:
$4.955
$18.89
Personalis Inc Stock (PSNL) Company Profile
Firmenname
Personalis Inc
Sektor
Branche
Telefon
650-752-1300
Adresse
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
16.57 | 1.77B | 64.52M | -95.55M | -84.65M | -1.0169 |
TMO
Thermo Fisher Scientific Inc
|
678.39 | 250.83B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
223.77 | 157.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
408.79 | 58.92B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
172.84 | 48.73B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
275.02 | 45.27B | 16.63B | 1.39B | 2.12B | 8.0674 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-05-15 | Eingeleitet | Guggenheim | Buy |
| 2025-03-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-06 | Hochstufung | Needham | Hold → Buy |
| 2022-01-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Herabstufung | Needham | Buy → Hold |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-20 | Bestätigt | Needham | Buy |
| 2021-05-06 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-12 | Bestätigt | Needham | Buy |
| 2020-11-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-07-15 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Personalis Inc Aktie (PSNL) Neueste Nachrichten
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL) - Supply Chain Digital Magazine
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL) - GlobeNewswire Inc.
Personalis President and CMO Richard Chen Executes Stock Sale for Tax Withholding - Kalkine Media
Personalis CLO Stephen Michael Moore Sells 2,068 Shares for RSU Tax Withholding - Kalkine Media
Tempus AI shares rise 5.1% to $70 on Moderna cancer trial validation - scanx.trade
TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight - Stocktwits
Personalis, Inc. (PSNL) Stock Analysis: A Bold Bet in Cancer Genomics with a 30% Revenue Surge - DirectorsTalk Interviews
Tempus move on Personalis (NASDAQ: PSNL) hinges on cancer tests and data from 50 million patients - Stock Titan
Tempus AI (TEM) Rallies As Upgrade, Earnings And Personalis Deal Align - timothysykes.com
Why Is PSNL Stock Up 5% After-Hours? - Stocktwits
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Weekly Recap: Intismeran win and Personalis 13% stake backs Tempus AI - TradingView
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits
Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation - finance.biggo.com
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels. - WSJ
Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next. - webull.com
Personalis Inc Stock Historical Valuations | FRA:04X - GuruFocus
Personalis Inc Stock Operating Data - GuruFocus
Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? - finance.yahoo.com
Why Personalis (PSNL) Is Up 24.0% After New VA MVP Genomics Task Order Win - webull.com
Personalis falls amid a downgrade as a competitive bid appears unlikely - Seeking Alpha
Tempus AI soars 40% in a week, adding $3.7 billion—over double the Personalis acquisition amount - TechStock²
Tempus AI (TEM) Is Up 39.5% After mRNA Melanoma Trial Win And Personalis DealWhat's Changed - finance.yahoo.com
A Look at Personalis Inc (PSNL) After 8.8% Gain -- GF Value $2.4 - GuruFocus
Tempus AI Shares Jump $3 Billion After Moderna Victory Boosts Value of $1.5 Billion Personalis Stake - TechStock²
Has Tempus AI (TEM) Run Too Far Ahead Of Its Valuation Narrative? - finance.yahoo.com
AMERIPRISE FINANCIAL INC Trims Personalis Inc (PSNL) Stake -- Shares Trade 590% Above GF Value - GuruFocus
Why Tempus AI (TEM) Is Up 22.8% After Buying the Platform Behind a Key mRNA Cancer Win - simplywall.st
Deep Track Capital, LP Trims Personalis Inc (PSNL) Stake -- Shar - GuruFocus
Personalis secures new Million Veteran Program task order - TipRanks
Personalis Receives New Task Order Under U.S. Veterans Affairs Contract For VA MVP - TradingView
Personalis wins up to $18.3M VA MVP task order, cumulative VA awards reach $243.3M - TradingView
Personalis (NASDAQ: PSNL) wins Million Veteran Program task order—how big is it? - Stock Titan
Tempus soars on coattails of Moderna/Merck cancer vaccine - Crain's Chicago Business
Personalis stock reaches 52-week high at 16.42 USD - Investing.com
Personalis stock reaches 52-week high at 16.42 USD By Investing.com - Investing.com Canada
Tempus AI Just Had Their Entire Strategy Validated By Moderna’s Vaccine Advance (TEM) - Seeking Alpha
Personalis | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Personalis Inc : PSNL - 247wallst.com
Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant - Yahoo Finance
Tempus AI Jumps 24% as Merck-Moderna mRNA Vaccine Win Lifts Personalis Deal - finance.biggo.com
TEM Stock Dips As Tempus AI Bets $1.5B On Personalis - StocksToTrade
Personalis Inc. (PSNL) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Tempus AI Soars as Merck-Moderna Cancer Trial Validates Personalis Acquisition - Benzinga
Tempus AI Stock Slides As $1.5B Personalis Bet Raises Stakes - timothysykes.com
What Personalis (PSNL)'s Rising Revenue But Deepening Losses Means For Shareholders - webull.com
Tempus Is Buying Cancer-Testing Partner Personalis for $1.5 Billion - RamaOnHealthcare
Ameriprise Financial (PSNL) discloses 5.8% ownership stake in Personalis common stock - Stock Titan
Deep Track Capital (PSNL) reports 4,000,000 Personalis shares, now under 5% ownership - Stock Titan
Sei Investments Co. Buys 83,040 Shares of Personalis, Inc. $PSNL - MarketBeat
Personalis, Inc. (PSNL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Finanzdaten der Personalis Inc-Aktie (PSNL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):